trial

A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia

NCTId NCT00645099
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 462 (actual)
Sponsored by Janssen-Cilag Farmaceutica Ltda.
Primary completion 2009-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
462 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2007-10
Primary completion
2009-04
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
OlanzapinePaliperidone

Sponsors

Janssen-Cilag Farmaceutica Ltda.Lead Sponsor

Sites

0 total

Linked catalysts

1
A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapi — primary completion2009-04

Facts & assertions

4 sourced
Enrollment
462
Phase
PHASE3
Primary Completion Date
2009-04
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
Paliperidone
drug
lead_sponsor
Janssen-Cilag Farmaceutica Ltda.
company
indication
Schizophrenia
indication
Schizophrenia
indication